Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA seeks comments on psychotropic substances, including kratom

By Brian Buntz | July 27, 2021

FDA logoThe FDA has announced that it is looking for feedback on seven drugs, including kratom (mitragynine, 7-hydroxymitragynine), a popular recreational drug that remains legal at the federal level. FDA has warned consumers not to use kratom, which targets opioid receptors in the brain. There are no FDA-approved uses for the psychotropic herbal extract.

WHO had reached out to FDA and other regulators about its plans to add seven drugs, including kratom, to its list of scheduled drugs. The notification spurred HHS to publish the request for comments in the Federal Register concerning the seven drugs.

Also included on the list are the following drugs:

  • 4F-MDMB-BICA (4F-MDMB-BUTICA) is a synthetic cannabinoid.
  • Brorphine is an opioid analgesic compound that has become a designer drug in recent years.
  • Metonitazene is a potent opioid.
  • Eutylone (bk-EBDB) is a stimulant that reportedly has similar psychoactive effects to MDMA but is more dangerous.
  • BMDP (3,4-Methylenedioxy-N-benzylcathinone) is a synthetic stimulant related to methamphetamine.
  • Phenibut is a central nervous system depressant available in the U.S. as a dietary supplement. U.S.S.R. and other communist countries in Eastern Europe formerly prescribed the drugs.

Filed Under: Drug Discovery
Tagged With: 4-Methylenedioxy-N-benzylcathinone, 4F-MDMB-BICA, 4F-MDMB-BUTICA, 7-hydroxymitragynine, BMDP (3, Brorphine, Eutylone, FDA, kratom, Metonitazene, mitragynine, Phenibut
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE